- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07910097
Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas
Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas in Patients With Primary Hyperparathyroidism
Study of Flurpiridaz F-18 positron emission tomography/computed tomography (PET/CT) as a diagnostic imaging tool to detect abnormal parathyroid glands in patients with primary hyperparathyroidism, prior to multi-parathyroid gland surgical exploration. Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 PET/CT versus standard of care dual time point sestamibi single photon emission computed computed tomography/computed tomography (SPECT/CT) imaging will be tested.
Study Overview
Detailed Description
Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 (fluorine-18) PET/CT versus standard of care dual time point sestamibi SPECT/CT imaging will be tested.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Erin Schubert, BA
- Phone Number: 215-573-6569
- Email: erin.schubert@pennmedicine.upenn.edu
Study Contact Backup
- Name: Mary Hansbury, BS
- Phone Number: 215-746-8192
- Email: mary.hansbury@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Unversity of Pennsylvania
-
Contact:
- Erin Schubert, BA
- Phone Number: 215-573-6569
- Email: erin.schubert@pennmedicine.upenn.edu
-
Contact:
- Mary Hansbury, BS
- Phone Number: 215-746-8192
- Email: mary.hansbury@pennmedicine.upenn.edu
-
Principal Investigator:
- Victor Babatunde, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients, at least 18 years of age
- History of primary hyperparathyroidism as clinically confirmed by serum laboratory values of elevated calcium levels (>10.2 mg/dl) and abnormal or inappropriately normal parathyroid hormone concentrations (normal range: 15 to 65 pg/ml).
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
- Participants must have had prior SPECT/CT sestamibi parathyroid imaging within 6 months of this investigational study or planned SPECT/CT sestamibi parathyroid imaging scheduled prior to this investigational study.
- Planned surgery within 6 months following this investigational study.
Exclusion Criteria:
- Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential ( as self-reported by menstrual history) before the injection of radiotracer.
- Inability to tolerate imaging procedures, including but not limited to claustrophobia, inability to remain still during scanning, or any other condition that, in the judgment of the investigator or treating physician, would interfere with safe or adequate imaging.
- Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Flycardo PET/CT
Flycardo PET/CT scan in patients with primary hyperparathyroidism |
Flurpiridaz is a FDA approved radiopharmaceutical used with PET/CT imaging |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity
Time Frame: 4 weeks
|
Qualitative positive or negative PET/CT |
4 weeks
|
|
sensitivity
Time Frame: 6 weeks
|
comparison of specificity of PET/CT imaging with standard dual-energy Sestamibi imaging |
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Victor Babatunde, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 859544
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.